Illumina Inc. (ILMN) has had a mixed financial year in 2025. After topping both Q1 earnings and revenue estimates, the company witnessed a drop in its shares by 3% despite beating Q1 EPS estimates. The company faced a lowered price target and adjusted EPS view triggered by tariffs and a sales ban from China that negatively impacted the company's outlook. As a consequence, ILMN shares saw a significant drop, and prominent funds such as Artisan Mid Cap Fund exited the company. Amid all the challenges, Illumina still continues to innovate by partnering with Tempus for genomic AI innovation and launching a major clinical Multiomic with Ovation.io. Despite challenges, it maintains its position as a strong value stock for the long-term according to experts.
Illumina ILMN News Analytics from Fri, 08 Nov 2024 08:00:00 GMT to Sat, 10 May 2025 14:57:29 GMT -
Rating -4
- Innovation 2
- Information 5
- Rumor -3
